News | August 07, 2024
Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Subscribe To Our Newsletter & Stay Updated
